Please Wait.....
Report
APAC Laboratory-Developed Tests (LDTs) Market - Industry Trends and Forecast to 2030
Market Report I 2023-06-01 I 341 Pages I Data Bridge Market Research
The Asia-Pacific Laboratory-Developed Tests (LDTs) market is expected to reach USD 9,607.08 Million by 2030 from USD 4,768.52 million in 2022, growing at a CAGR of 9.2% during the forecast period of 2023 to 2030.
Market Segmentation
Asia-Pacific Laboratory-Developed Tests (LDTs) Market, By Test Type (Clinical Chemistry and Immunology, Critical Care, Hematology, Molecular Diagnostics, Microbiology, and Other Test), Product Type (Consumables, Analyzers and Instruments, and Accessories), Sample Type (Blood, Urine, Tissue, Cerebrospinal Fluid (CSF), and Others), Therapeutic Area (Infections, Genetic Disorders, Oncology/Cancer, Autoimmune Disease, Urology, Gynecology, and Others), Gender (Male, and Female), Age Group (Geriatrics, Adult, and Pediatric), End Users (Hospital-Based Labs, Stand-Alone Labs, Diagnostic Chains, Academic Institutes, Clinical Research Organizations, Specialty Diagnostic Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, Third Party Distributors, and Others), Country (China, Japan, India, Australia, South Korea, Indonesia, Philippines, Thailand, Malaysia, Singapore, Rest of Asia Pacific) - Industry Trends and Forecast to 2030
Overview of Asia-Pacific Laboratory-Developed Tests (LDTs) Market Dynamics
Drivers
- Increasing demand for personalized medicines
- Advancements in molecular diagnostics
Restraint
- Stringent quality control and standardization for LDTs
Opportunity
- Increasing demand for precision medicine and targeted therapy
Market Players
Some of the major market players operating in the Asia-Pacific Laboratory-Developed Tests (LDTs) market are:
- F. Hoffmann-La Roche Ltd
- bioMerieux, Inc.
- Sysmex Corporation
- Biomerica, Inc.
- Bio-Rad Laboratories, Inc.
- Abbott
- Siemens Medical Solutions USA, Inc.
- Quest Diagnostics Incorporated
- QIAGEN
- Eurofins Scientific
- Biodesix.
- Hologic, Inc.
- Guardant Health
- OPKO Health, Inc.
- BD
- Beckman Coulter, Inc.
- NeoGenomics Laboratories.
- Seegene Inc.
- BGI
- 23andMe, Inc.
- Agendia
TABLE OF CONTENTS
1 INTRODUCTION 66
1.1 OBJECTIVES OF THE STUDY 66
1.2 MARKET DEFINITION 66
1.3 OVERVIEW OF THE ASIA PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET 66
1.4 CURRENCY AND PRICING 68
1.5 LIMITATIONS 68
1.6 MARKETS COVERED 68
2 MARKET SEGMENTATION 73
2.1 MARKETS COVERED 73
2.2 GEOGRAPHICAL SCOPE 74
2.3 YEARS CONSIDERED FOR THE STUDY 75
2.4 DBMR TRIPOD DATA VALIDATION MODEL 76
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 79
2.6 MULTIVARIATE MODELLING 80
2.7 TEST TYPE SEGMENT LIFELINE CURVE 80
2.8 MARKET END USER COVERAGE GRID 81
2.9 DBMR MARKET POSITION GRID 82
2.10 VENDOR SHARE ANALYSIS 83
2.11 SECONDARY SOURCES 84
2.12 ASSUMPTIONS 84
3 EXECUTIVE SUMMARY 85
4 PREMIUM INSIGHTS 88
4.1 PESTEL ANALYSIS 89
4.2 PORTER'S FIVE FORCES MODEL 90
5 INDUSTRY INSIGHTS 91
6 NUMBER OF LABS 93
6.1 NUMBER OF LABS IN MIDDLE EASTERN COUNTRIES 93
6.2 NUMBER OF LABS IN EUROPE 93
7 REGULATIONS OF THE ASIA PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET 95
7.1 SINGAPORE 96
7.2 CHINA 96
8 MARKET OVERVIEW 98
8.1 DRIVERS 100
8.1.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE 100
8.1.2 ADVANCEMENTS IN MOLECULAR DIAGNOSTICS 100
8.1.3 GROWING PREVALENCE OF CHRONIC DISEASES 100
8.1.4 INCREASING AWARENESS AND ACCEPTANCE TOWARDS THE ASSISTANCES OF LDTS 101
8.2 RESTRAINTS 101
8.2.1 STRINGENT QUALITY CONTROL AND STANDARDIZATION FOR LDTS 101
8.2.2 STRICT REGULATORY GUIDELINES REGARDING LDTS 102
8.3 OPPORTUNITIES 102
8.3.1 INCREASING DEMAND FOR PRECISION MEDICINE AND TARGETED THERAPY 102
8.3.2 ENHANCED HEALTHCARE SUBSTRUCTURE 103
8.4 CHALLENGES 103
8.4.1 DEPRIVED DATA INTERPRETATION AND INTEGRATION 103
8.4.2 COMPLEX LABORATORY PROCESSES 104
9 ASIA PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY TEST TYPE 105
9.1 OVERVIEW 106
9.2 CLINICAL CHEMISTRY AND IMMUNOLOGY 109
9.2.1 GLUCOSE 110
9.2.1.1 GLUCOSE CHALLENGE TEST 110
9.2.1.2 ORAL GLUCOSE TOLERANCE TEST (OGTT) 110
9.2.2 PROTHROMBIN 111
9.2.3 METABOLIC PANEL 111
9.2.3.1 BASIC 111
9.2.3.2 COMPREHENSIVE 111
9.2.4 LIPID PANEL 111
9.2.5 LIVER PANEL 111
9.2.5.1 ALP TEST (ALKALINE PHOSPHATE) 112
9.2.5.2 ALT TEST (ALKALINE TRANSMINASE) 112
9.2.5.3 AST TEST (ASPARTATE AMINOTRANSFERASE) 112
9.2.5.4 GAMMA-GLUTAMYL TRANSFERASE (GGT) TEST 112
9.2.6 THYROID STIMULATING HORMONE 112
9.2.7 URINALYSIS 112
9.2.7.1 RED BLOOD CELL URINE TEST 113
9.2.7.2 GLUCOSE URINE TEST 113
9.2.7.3 PROTEIN URINE TEST 113
9.2.7.4 URINE PH LEVEL 113
9.2.7.5 KETONES URINE TEST 113
9.2.7.6 BILIBURIN URINE TEST 113
9.2.7.7 URINE SPECIFIC GRAVITY TEST 114
9.2.8 OTHERS 114
9.3 CRITICAL CARE 114
9.3.1 CARBOXYHAEMOGLOBIN TEST 115
9.3.2 PH TEST 115
9.3.3 POTASSIUM TEST 115
9.3.4 SODIUM TEST 115
9.3.5 METHEMOGLOBIN TEST 115
9.3.6 LACTATE TEST 115
9.3.7 OTHERS 116
9.4 HAEMATOLOGY 116
9.4.1 COMPLETE BLOOD COUNT (CBC) 117
9.4.1.1 WHITE BLOOD CELL COUNT (WBC) 117
9.4.1.2 RED BLOOD CELL COUNT (RBC) 117
9.4.2 PLATELET COUNT 117
9.4.3 BLOOD PROTEIN TESTING 118
9.4.4 OTHERS 118
9.5 MOLECULAR DIAGNOSTIC 118
9.5.1 SAMPLE TYPE 119
9.5.1.1 BLOOD 119
9.5.1.2 URINE 119
9.5.1.3 TISSUE 119
9.5.1.4 CEREBROSPINAL FLUID (CSF) 119
9.5.1.5 OTHERS 119
9.5.2 THERAPEUTIC AREA 119
9.5.2.1 INFECTIONS 120
9.5.2.2 GENETIC DISORDERS 120
9.5.2.3 ONCOLOGY/CANCER 120
9.5.2.4 AUTOIMMUNE DISEASE 120
9.5.2.5 UROLOGY 120
9.5.2.6 GYNECOLOGY 120
9.5.2.7 OTHERS 120
9.5.3 TECHNOLOGY 121
9.5.3.1 POLYMERASE CHAIN REACTION (PCR) 121
9.5.3.2 NEXT-GENERATION SEQUENCING (NGS) 121
9.5.3.3 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 121
9.5.3.4 SANGER SEQUENCING 121
9.5.3.5 MICROARRAYS 121
9.5.3.6 MASS SPECTROMETRY 122
9.5.3.7 ISOTHERMAL AMPLIFICATION 122
9.5.4 END USER 122
9.5.4.1 HOSPITAL-BASED LABS 122
9.5.4.2 STAND-ALONE LABS 122
9.5.4.3 DIAGNOSTIC CHAINS 122
9.5.4.4 ACADEMIC INSTITUTES 123
9.5.4.5 CLINICAL RESEARCH ORGANIZATIONS 123
9.5.4.6 SPECIALTY DIAGNOSTIC CENTERS 123
9.5.4.7 OTHERS 123
9.6 MICROBIOLOGY 123
9.6.1 MICROSCOPY 124
9.6.2 CULTURE 124
9.6.3 ANTIMICROBIAL SUSCEPTIBILITY TEST 124
9.6.4 OTHERS 124
9.7 OTHER TEST 125
9.7.1 DRUGS OF ABUSE TESTING 126
9.7.2 HEPATITIS 126
9.7.3 HUMAN IMMUNODEFICIENCY VIRUSES (HIV) 126
9.7.4 MALARIA 126
9.7.5 TUBERCULOSIS 126
9.7.6 HUMAN PAPILLOMAVIRUS (HPV) 126
9.7.7 OTHERS 127
10 ASIA PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY PRODUCT TYPE 128
10.1 OVERVIEW 129
10.2 CONSUMABLES 132
10.2.1 PANELS 132
10.2.2 REAGENT AND KITS 133
10.2.3 OTHERS 133
10.3 ANALYZERS AND INSTRUMENTS 133
10.3.1 FULLY-AUTOMATED INSTRUMENTS 134
10.3.2 SEMI-AUTOMATED INSTRUMENTS 134
10.3.3 OTHERS 134
10.4 ACCESSORIES 134
11 ASIA PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY SAMPLE TYPE 136
11.1 OVERVIEW 137
11.2 BLOOD 140
11.3 URINE 140
11.4 TISSUE 141
11.5 CEREBROSPINAL FLUID (CSF) 141
11.6 OTHERS 142
12 ASIA PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY THERAPEUTIC AREA 144
12.1 OVERVIEW 145
12.2 INFECTIONS 148
12.2.1 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) 149
12.2.2 CLOSTRIDIUM DIFFICILE 149
12.2.3 VANCOMYCIN-RESISTANT ENTEROCOCCI (VRE) 149
12.2.4 CARBAPENEM-RESISTANT BACTERIA 149
12.2.5 FLU 149
12.2.6 RESPIRATORY SYNCYTIAL VIRUS (RSV) 150
12.2.7 CANDIDA 150
12.2.8 TUBERCULOSIS AND DRUG-RESISTANT TBA 150
12.2.9 MENINGITIS 150
12.2.10 GASTROINTESTINAL PANEL TESTING 150
12.2.11 CHLAMYDIA 150
12.2.12 GONORRHEA 150
12.2.13 HIV 150
12.2.14 HEPATITIS B 150
12.2.15 HEPATITIS C 150
12.2.16 OTHER INFECTIOUS DISEASES 150
12.3 GENETIC DISORDERS 151
12.3.1 NEW BORN SCREENING 151
12.3.2 PREDICTIVE AND PRESYMPTOMATIC TESTING 152
12.3.3 OTHER GENETIC TESTING 152
12.4 OCNOLOGY/CANCER 152
12.4.1 BREAST CANCER 153
12.4.2 PROSTATE CANCER 153
12.4.3 COLORECTAL CANCER 153
12.4.4 CERVICAL CANCER 153
12.4.5 KIDNEY CANCER 153
12.4.6 LIVER CANCER 153
12.4.7 BLOOD CANCER 153
12.4.8 LUNG CANCER 154
12.4.9 OTHER CANCER 154
12.5 AUTOIMMUNE DISEASE 154
12.6 UROLOGY 154
12.7 GYNECOLOGY 155
12.8 OTHERS 156
13 ASIA PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY GENDER 157
13.1 OVERVIEW 158
13.2 MALE 161
13.3 FEMALE 161
14 ASIA PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY AGE GROUP 163
14.1 OVERVIEW 164
14.2 GERIATRICS 167
14.3 ADULT 167
14.4 PEDIATRICS 168
15 ASIA PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY END USER 169
15.1 OVERVIEW 170
15.2 HOSPITAL-BASED LABS 173
15.3 STAND -ALONE LABS 173
15.4 DIAGNOSTIC CHAINS 174
15.5 ACADEMIC INSTITUTES 175
15.6 CLINICAL RESEARCH ORGANISTAION 175
15.7 SPECIALTY DIAGNOSTIC 176
15.8 OTHERS 177
16 ASIA PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY DISTRIBUTION CHANNEL 178
16.1 OVERVIEW 179
16.2 DIRECT TENDER 182
16.3 RETAIL SALES 182
16.4 THIRD PARTY DISTRIBUTORS 183
16.5 OTHERS 184
17 ASIA PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET, BY REGION 185
17.1 ASIA PACIFIC 186
17.1.1 CHINA 200
17.1.2 JAPAN 209
17.1.3 INDIA 218
17.1.4 AUSTRALIA 227
17.1.5 SOUTH KOREA 236
17.1.6 INDONESIA 245
17.1.7 PHILIPPINES 254
17.1.8 THAILAND 263
17.1.9 MALAYSIA 272
17.1.10 SINGAPORE 281
17.1.11 REST OF ASIA-PACIFIC 290
18 ASIA PACIFIC LABORATORY-DEVELOPED TESTS (LDTS) MARKET, COMPANY LANDSCAPE 291
18.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 291
19 COMPANY PROFILES 292
19.1 F. HOFFMANN-LA ROCHE LTD. 292
19.1.1 COMPANY SNAPSHOT 292
19.1.2 REVENUE ANALYSIS 292
19.1.3 COMPANY SHARE ANALYSIS 293
19.1.4 PRODUCT PORTFOLIO 293
19.1.5 RECENT DEVELOPMENT 293
19.2 BIOMERIEUX 294
19.2.1 COMPANY SNAPSHOT 294
19.2.2 REVENUE ANALYSIS 294
19.2.3 COMPANY SHARE ANALYSIS 295
19.2.4 PRODUCT PORTFOLIO 295
19.2.5 RECENT DEVELOPMENTS 295
19.3 SYSMEX CORPORATION 296
19.3.1 COMPANY SNAPSHOT 296
19.3.2 REVENUE ANALYSIS 296
19.3.3 COMPANY SHARE ANALYSIS 297
19.3.4 PRODUCT PORTFOLIO 297
19.3.5 RECENT DEVELOPMENT 297
19.4 BIOMERICA. 298
19.4.1 COMPANY SNAPSHOT 298
19.4.2 REVENUE ANALYSIS 298
19.4.3 COMPANY SHARE ANALYSIS 299
19.4.4 PRODUCT PORTFOLIO 299
19.4.5 RECENT DEVELOPMENT 299
19.5 BIO-RAD LABORATORIES, INC 300
19.5.1 COMPANY SNAPSHOT 300
19.5.2 REVENUE ANALYSIS 300
19.5.3 COMPANY SHARE ANALYSIS 301
19.5.4 PRODUCT PORTFOLIO 301
19.5.5 RECENT DEVELOPMENT 301
19.6 23ANDME, INC. 302
19.6.1 COMPANY SNAPSHOT 302
19.6.2 REVENUE ANALYSIS 302
19.6.3 PRODUCT PORTFOLIO 303
19.6.4 RECENT DEVELOPMENTS 303
19.7 ABBOTT 304
19.7.1 COMPANY SNAPSHOT 304
19.7.2 REVENUE ANALYSIS 304
19.7.3 PRODUCT PORTFOLIO 305
19.7.4 RECENT DEVELOPMENT 305
19.8 ADMERA HEALTH 306
19.8.1 COMPANY SNAPSHOT 306
19.8.2 PRODUCT PORTFOLIO 306
19.8.3 RECENT DEVELOPMENT 306
19.9 AGENDIA. 307
19.9.1 COMPANY SNAPSHOT 307
19.9.2 PRODUCT PORTFOLIO 307
19.9.3 RECENT DEVELOPMENT 307
19.10 AMBRY GENETICS 308
19.10.1 COMPANY SNAPSHOT 308
19.10.2 PRODUCT PORTFOLIO 308
19.10.3 RECENT DEVELOPMENT 309
19.11 BD 310
19.11.1 COMPANY SNAPSHOT 310
19.11.2 REVENUE ANALYSIS 310
19.11.3 PRODUCT PORTFOLIO 311
19.11.4 RECENT DEVELOPMENTS 311
19.12 BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER) 312
19.12.1 COMPANY SNAPSHOT 312
19.12.2 REVENUE ANALYSIS 312
19.12.3 PRODUCT PORTFOLIO 313
19.12.4 RECENT DEVELOPMENTS 313
19.13 BGI. 314
19.13.1 COMPANY SNAPSHOT 314
19.13.2 PRODUCT PORTFOLIO 314
19.13.3 RECENT DEVELOPMENT 315
19.14 BIODESIX. 316
19.14.1 COMPANY SNAPSHOT 316
19.14.2 REVENUE ANALYSIS 316
19.14.3 PRODUCT PORTFOLIO 317
19.14.4 RECENT DEVELOPMENTS 317
19.15 EUROFINS SCIENTIFIC 318
19.15.1 COMPANY SNAPSHOT 318
19.15.2 REVENUE ANALYSIS 318
19.15.3 PRODUCT PORTFOLIO 319
19.15.4 RECENT DEVELOPMENT 319
19.16 GUARDANT HEALTH 320
19.16.1 COMPANY SNAPSHOT 320
19.16.2 REVENUE ANALYSIS 320
19.16.3 PRODUCT PORTFOLIO 321
19.16.4 RECENT DEVELOPMENTS 321
19.17 HOLOGIC, INC. 322
19.17.1 COMPANY SNAPSHOT 322
19.17.2 REVENUE ANALYSIS 322
19.17.3 PRODUCT PORTFOLIO 323
19.17.4 RECENT DEVELOPMENT 323
19.18 MILAB SCIENTIFIC. 324
19.18.1 COMPANY SNAPSHOT 324
19.18.2 PRODUCT PORTFOLIO 324
19.18.3 RECENT DEVELOPMENT 324
19.19 NEOGENOMICS LABORATORIES 325
19.19.1 COMPANY SNAPSHOT 325
19.19.2 REVENUE ANALYSIS 325
19.19.3 PRODUCT PORTFOLIO 326
19.19.4 RECENT DEVELOPMENTS 326
19.20 OPKO HEALTH, INC. 327
19.20.1 COMPANY SNAPSHOT 327
19.20.2 REVENUE ANALYSIS 327
19.20.3 PRODUCT PORTFOLIO 328
19.20.4 RECENT DEVELOPMENT 328
19.21 QIAGEN 329
19.21.1 COMPANY SNAPSHOT 329
19.21.2 REVENUE ANALYSIS 329
19.21.3 PRODUCT PORTFOLIO 330
19.21.4 RECENT DEVELOPMENTS 330
19.22 QUEST DIAGNOSTICS INCORPORATED. 331
19.22.1 COMPANY SNAPSHOT 331
19.22.2 REVENUE ANALYSIS 331
19.22.3 PRODUCT PORTFOLIO 332
19.22.4 RECENT DEVELOPMENTS 332
19.23 SEEGENE INC 333
19.23.1 COMPANY SNAPSHOT 333
19.23.2 REVENUE ANALYSIS 333
19.23.3 PRODUCT PORTFOLIO 334
19.23.4 RECENT DEVELOPMENT 334
19.24 SIEMENS HEALTHCARE GMBH 335
19.24.1 COMPANY SNAPSHOT 335
19.24.2 REVENUE ANALYSIS 335
19.24.3 PRODUCT PORTFOLIO 336
19.24.4 RECENT DEVELOPMENT 336
20 QUESTIONNAIRE 337
21 RELATED REPORTS 341
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security